Net revenues increased by 6.4% to $143.4 million in 2025 from $134.9 million in 2024. Net income surged by 180.0% to $6.6 million in 2025 from $2.3 million in 2024. Patient Services net revenue grew by 7.7% to $86.5 million, primarily due to increased treatment volume in Oncology and Wound Care. Device Solutions net revenue increased by 4.4% to $56.9 million, driven by higher rental revenue, medical equipment sales, and biomedical services. Gross profit rose by 14.1% to $80.3 million, with gross margin improving to 56.0% from 52.2% in the prior year. Operating income increased by $5.0 million to $11.9 million in 2025. The company repurchased $9.9 million of common stock in 2025 under its $20.0 million share repurchase program. Cash and cash equivalents increased to $3.2 million at year-end 2025 from $0.5 million in 2024. Long-term debt decreased to $20.0 million (outstanding draws) from $24.1 million in 2024.